Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 plus dacarbazine in metastatic melanoma
2007-005737-11Phase 2Terminated
- Sponsor
- Philogen
- Start
- Dec 2007
- Modality
- Small Molecules, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of darleukin and dacarbazine in melanoma (2 arms), sponsored by Philogen. Primary endpoints: Recommended dose of L19IL2 in combination with dacarbazine and Preliminary tolerability profile. Started Dec 2007; status: terminated.
02
Drugs
darleukindacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-005737-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005737-11.